NeoChord, Inc.
Industry
- Medical Devices
- Implantable Devices
- Surgical Equipment & Devices
- Minimally or Less Invasive
Other Names/Subsidiaries
- Shanghai Houchao Biotechnology Co Ltd
Latest on NeoChord, Inc.
Edwards Lifesciences Corp. acquisition of Baltimore-based Harpoon Medical Inc. gives Edwards another minimally invasive tool to treat diseased mitral valves and rewards the faith of Epidarex Cap
Total worldwide sales of heart valve disease treatment systems are set to expand at a compound annual growth rate (CAGR) of 10.9%, increasing from approximately $4,8 billion in 2016 to an estimated $8
Company Changes ADENT , John To: Neogen Corp. , CEO (July) From: Animal Health International, CEO Phone: 517-372-9200 ARENA , Paul To: Parallax Health Sciences Inc. , CEO (July) From: Arena
The global market for products treating heart valve disease is forecast to grow from $4.8bn in 2016 to $8.1bn in 2021, at a compound annual growth rate (CAGR) of 10.9%. According to Meddevicetracker